About EBC-46

About EBC-46

What is EBC-46

EBC-46 is a novel anti-cancer drug discovered by applying the EcoLogicTM approach to drug discovery from the rainforests of Northern Queensland. This approach has resulted in a drug therapy for solid tumour cancers that is significantly different to other cancer treatments in the market.

For Animals
EBC-46 is proving to be an outstanding anti-cancer drug with potential to revolutionise the way solid tumours are treated in companion animals. To date, EBC-46 has been successful in the treatment of a diverse range of inoperable solid tumours in dogs, cats and horses. In each case tumour destruction occurred within days with rapid healing of the site and no significant side effects. Click here to learn more

For Humans
As the principles behind the formation of cancer between animals and humans are similar it is expected that EBC-46 will have similar effects in humans as in animals. Clinical Phase I trials for EBC-46 in humans is expected to commence in Australia early 2011. Click here to learn more


Home

About QBiotics

Snapshot

Business Structure

Our Business Overview

Mission

Strategy

Milestones

Corporate Responsibility

Values & Culture

Governance

Natural Environment

In The Community

About EBC-46

What Is EBC-46

How Does It Work

EBC-46 Discovery

Development

EBC-46 Results

Results

Case Studies

Photo Gallery

Our Team

Board & Management

Research & Development

Partners

Media

Video

Press

Latest News

Media Enquiries

Investors

Register For Upcoming Offers

Download Our Corporate Profile

EBC-46 & Animals

Clinical Trials

Enquiries

EBC-46 & Humans

Clinical Trials

Enquiries

FAQ

Newsletter

Newsletter Sign up

Contact Us

General Enquiries

EBC-46 & Animals

Clinical Trail Enquiries

Media Enquiries